1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 39, 29/Sep/2022
  4. Article
Rapid communication Open Access
Like 1
Download

Abstract

While two influenza B virus lineages have co-circulated, B/Yamagata-lineage circulation has not been confirmed since March 2020. The WHO FluNet database indicates that B/Yamagata-lineage detections were reported in 2021 and 2022. However, detections can result from use of quadrivalent live-attenuated vaccines. Of the type B viruses detected post-March 2020, all ascribed to a lineage have been B/Victoria-lineage. There is need for a global effort to detect and lineage-ascribe type B influenza viruses, to assess if B/Yamagata-lineage viruses have become extinct.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.39.2200753
2022-09-29
2024-12-22
/content/10.2807/1560-7917.ES.2022.27.39.2200753
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/39/eurosurv-27-39-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.39.2200753&mimeType=html&fmt=ahah

References

  1. Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721.  https://doi.org/10.1038/s41467-022-29402-5  PMID: 35361789 
  2. World Health organization (WHO). FluNet. Global Influenza Programme. Geneva: WHO. [Accessed: 14 Aug 2022]. Available from: https://www.who.int/tools/flunet
  3. Center for Systems Science and Engineering (CSSE). COVID-19 Dashboard. Baltimore: Johns Hopkins University. [Accessed 14 Aug 2022]. Available from: https://coronavirus.jhu.edu/map.html
  4. Global initiative on sharing all influenza data (GISAID). EpiFlu database. Munich: GISAID. [Accessed: 29 Aug 2022]. Available from: www.gisaid.org
  5. World Health organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022- 2023 northern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2022-2023/202202_recommendation.pdf?sfvrsn=5c88e006_13&download=true
  6. Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14(9):e0222381.  https://doi.org/10.1371/journal.pone.0222381  PMID: 31513690 
  7. European Centre for Disease Prevention and Control (ECDC) and World Health Organization Regional Office for Europe. (WHO/Europe). European External Influenza Virus Quality Assessment Programme – 2020 data. Stockholm and Copenhagen: ECDC and WHO/Europe; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/20220204-report-EEIQAP-2020.pdf
  8. World Health Organization (WHO). External Quality Assessment Programme for the Detection of Influenza Viruses by RT-PCR, Participant Summary Report, Panel 20. Geneva: WHO; 31 December 2021. Forthcoming 2022.
  9. Huang WJ, Cheng YH, Tan MJ, Liu J, Li XY, Zeng XX, et al. Epidemiological and virological surveillance of influenza viruses in China during 2020-2021. Infect Dis Poverty. 2022;11(1):74.  https://doi.org/10.1186/s40249-022-01002-x  PMID: 35768826 
  10. World Health Organization (WHO). Influenza (seasonal). Geneva: WHO; 2018. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
  11. Virk RK, Jayakumar J, Mendenhall IH, Moorthy M, Lam P, Linster M, et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci USA. 2020;117(1):619-28.  https://doi.org/10.1073/pnas.1916585116  PMID: 31843889 
  12. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YCF, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. eLife. 2015;4:e05055.  https://doi.org/10.7554/eLife.05055  PMID: 25594904 
  13. Center for Infectious Disease Research and Policy (CIDRAP). FDA clears first quadrivalent flu vaccine. Minneapolis: CIDRAP; 2012. Available from: https://www.cidrap.umn.edu/news-perspective/2012/03/fda-clears-first-quadrivalent-flu-vaccine
  14. Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, Smith DJ, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol. 2011;18(3):469-76.  https://doi.org/10.1128/CVI.00396-10  PMID: 21209157 
  15. European Medicines Agency (EMA). Fluenz Tetra. Influenza vaccine (live attenuated, nasal). Amsterdam: EMA; 2016. Available from: https://www.ema.europa.eu/en/documents/overview/fluenz-tetra-epar-summary-public_en.pdf
  16. Bennett S, MacLean AR, Reynolds A, von Wissmann B, Gunson RN. False positive influenza A and B detections in clinical samples due to contamination with live attenuated influenza vaccine. J Med Microbiol. 2015;64(Pt 4):466-8.  https://doi.org/10.1099/jmm.0.000035  PMID: 25657303 
  17. Curran T, McCaughey C, Ellis J, Mitchell SJ, Feeney SA, Watt AP, et al. False-positive PCR results linked to administration of seasonal influenza vaccine. J Med Microbiol. 2012;61(Pt 3):332-8.  https://doi.org/10.1099/jmm.0.036178-0  PMID: 22096134 
  18. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, March 2022. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Influenza-characterisation-report-march-2022.pdf
  19. Merced-Morales A, Daly P, Abd Elal AI, Ajayi N, Annan E, Budd A, et al. influenza activity and composition of the 2022-23 influenza vaccine - United States, 2021-22 season. MMWR Morb Mortal Wkly Rep. 2022;71(29):913-9.  https://doi.org/10.15585/mmwr.mm7129a1  PMID: 35862284 
  20. Mackenzie GA, Vilane A, Salaudeen R, Hogerwerf L, van den Brink S, Wijsman LA, et al. Respiratory syncytial, parainfluenza and influenza virus infection in young children with acute lower respiratory infection in rural Gambia. Sci Rep. 2019;9(1):17965.  https://doi.org/10.1038/s41598-019-54059-4  PMID: 31784567 
  21. Centers for Disease Control and Prevention (CDC). CDC laboratory support for influenza surveillance (CLSIS) sharepoint site. Atlanta: CDC. [Accessed: 22 Sep 2022]. Available from: https://cdn.who.int/media/docs/default-source/influenza/global-influenza-surveillance-and-response-system/related-documents/cdc_laboratory_support_for_influenza_surveillance_info_sheet_aug2017.pdf?sfvrsn=83d8b6e3_10
Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=John+Paget&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Paget John</a>, <a href="/search?value1=Saverio+Caini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Caini Saverio</a>, <a href="/search?value1=Marco+Del+Riccio&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Del Riccio Marco</a>, <a href="/search?value1=Willemijn+van+Waarden&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Waarden Willemijn</a>, <a href="/search?value1=Adam+Meijer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meijer Adam</a></span>. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(39):pii=2200753. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Sept 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 28 Sept 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.39.2200753
/content/10.2807/1560-7917.ES.2022.27.39.2200753
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error